Results 141 to 150 of about 6,357 (207)

ANEMIA INDUZIDA PELO CANCRO, TRATAMENTO E CONTROVÉRSIAS [PDF]

, 2012
Luísa Catarina Nunes Sousa
core  

A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment

Health Technology Assessment, 2007
J Wilson, G Yao, J Raftery, J Bohlius, S Brunskill, J Sandercock, S Bayliss, P Moss, S Stanworth, C Hyde   +9 more
doaj   +1 more source

Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis. [PDF]

BMC Nephrol
Hassan MF, Bin Faheem MS, Cheema S, Henna F, Javid S, Islam MR, Habib I, Usman M, Kurmasha YH, Samadi S, Mohammad YN.   +10 more
europepmc   +1 more source

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
. [PDF]

Clin Nephrol, 2017
Casadevall N, Dobronravov V, Eckardt KU, Ertürk S, Martynyuk L, Schmitt S, Schaffar G, Rudy A, Krendyukov A, Ode M.   +9 more
europepmc   +1 more source

Roxadustat for renal anemia: current clinical experience. [PDF]

Front Pharmacol
Ji J, Li Z, Fang S, Li Z.
europepmc   +1 more source

Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.

Am J Nephrol, 2018
Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan Jahromi S, Sanadgol H, Amini S, Shahvaroughi Farahani A.   +8 more
europepmc   +1 more source

Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan. [PDF]

Ther Innov Regul Sci
Matsumoto M, Kumazawa R, Ishii-Watabe A, Horiguchi I, Mamiya H, Shibata H, Saito Y, Adomi M, Taniguchi Y, Komiyama J, Sakai R, Iwagami M.   +11 more
europepmc   +1 more source

Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.

J Am Soc Nephrol, 2016
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ.   +13 more
europepmc   +1 more source

NEW STRENGTHS: Epoetin alfa

Australian Prescriber, 2000
openaire   +1 more source

Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature. [PDF]

Cureus
Pothacamuri MA, Venugopal A, Chandrashekar N, Banderas Echeverry WM, Appiah JG, AlSalami S, Ahmed K, Alasaadi S, Almutairi AZ, Mbaekwe E, Bodapati N, Ali R.   +11 more
europepmc   +1 more source